|
Basic InformationLatest NewsAutopsy Study May Explain Why Some COVID Survivors Have 'Brain Fog'Gene Study Probes Origins of Addison's DiseaseCould a Common Prostate Drug Help Prevent Parkinson's?AHA News: Hormones Are Key in Brain Health Differences Between Men and WomenNerve Drug Might Curb Spinal Cord Damage, Mouse Study SuggestsIs There a 'Risk-Taking' Center in the Brain?AHA News: Dr. Dre Recovering From a Brain Aneurysm. What Is That?Can 2 Nutrients Lower Your Risk for Parkinson's?New Clues to How Cancers Originate in the BrainBrain May Age Faster After Spinal Cord InjuryScans Reveal How COVID-19 Can Harm the BrainWhat Loneliness Looks Like in the BrainNeurologists Much Tougher to Find in Rural AmericaCOVID-19 Survival Declines When Brain Affected: StudyAs Testing Costs Rise, Neurology Patients May Skip ScreeningGene Therapy Shows No Long-Term Harm in Animals: StudyCould Gene Therapy Cure Sickle Cell Disease? Two New Studies Raise HopesCocoa Might Give Your Brain a Boost: StudyLockdown Loneliness Could Worsen Parkinson's SymptomsChildhood Lead Exposure Tied to Brain Changes in Middle AgeStaying Social Can Boost Healthy 'Gray Matter' in Aging BrainsDNA Analysis Might Reveal Melanoma RiskGenetics Might Explain Some Cases of Cerebral PalsyDiabetes Drug Metformin May Protect the Aging BrainNew Research Links Another Gene to Alzheimer's RiskYour Sex Affects Your Genes for Body Fat, Cancer, Birth WeightExperimental Drug Shows Promise Against ALSCould Gene Therapy Stem the Damage of Parkinson's?Genetic Research May Help Identify Causes of StillbirthBlood Test Heralds New Era in Alzheimer's DiagnosisMore Clues to the Genes Behind Hearing LossScientists Move Closer to Mapping Entire Human GenomeBlood Test May Reveal Concussion Severity With Accuracy of Spinal TapDeep Brain Stimulation May Slow Parkinson's, Study FindsStroke, Confusion: COVID-19 Often Impacts the Brain, Study ShowsYour Genes May Affect How You'll Heal If WoundedEven Without Concussion, Athletes' Brains Can Change After Head Jolts: StudyHealthDay In-Depth The AI Revolution: For Patients, Promise and Challenges Ahead">HealthDay In-Depth The AI Revolution: For Patients, Promise and Challenges AheadHealthDay In-Depth The AI Revolution: Giving Docs a Diagnostic Assist">HealthDay In-Depth The AI Revolution: Giving Docs a Diagnostic AssistBlood Test Might Predict Worsening MSKeto Diet Might Change Your Gut in More Ways Than OneParkinson's Patient Improving After First-Ever Stem Cell TherapyKey Areas of the Brain Triggered in Recent Heart Attack SurvivorsFirst Good Evidence That Brain Hits 'Replay' While You SleepSome NFL Players May Be Misdiagnosed With Brain Disease: StudyGreenhouse Gases Bad for Your BrainTransplanted Skin Stem Cells Help Blind Mice See LightBrain Plaques Signal Alzheimer's Even Before Other Symptoms Emerge: Study'It's Like You Have a Hand Again': New Prosthetic Gets Closer to the Real ThingDeep Brain Stimulation May Hold Promise in Alzheimer's Questions and AnswersLinksBook Reviews |
| |
by Joseph Glenmullen Simon & Schuster, 2000 Review by Christian Perring, Ph.D. on Jun 30th 2001 
I was skeptical about this book before reading it. I'd read a few reviews,
and I got the impression that is was alarmist and self-serving. The reviews
focused on Glenmullen's discussion
of severe side effects of SSRI (selective serotonin reuptake inhibitors)
antidepressants, such as bodily tics and powerful muscle spasms, and reported
that these problems were comparable to the tardive dyskinesia that sometimes
results from antipsychotic medications. The symptoms can persist even after
one has discontinued the medication, sometimes for months, and maybe longer.
This all sounded very similar to the criticisms of Peter
Breggin and psychiatric survivors groups,
who tend to overplay their hands, and who have been making alarming claims
about the side effects of medication for many years.
However, on reading Prozac Backlash I found it to be a far more
careful and balanced book than I expected, and, for me, its most important
message is about the power (and abuses of power) of pharmaceutical corporations.
Glenmullen's descriptions of the way the major psychotropic drug manufacturers
place business above truth and patient welfare, and how they are capable
of influencing the decisions not only of the psychiatric profession but
also the FDA are shocking. I'd strongly recommend that anyone involved
in the mental health profession and people who are taking or considering
medication to read at least a few crucial chapters of this book. It will
provide a foil to the simplistic and deceptive advertisements that now
appear regularly on TV and in national magazines for Prozac, Zoloft, Paxil,
and other SSRIs, and to the beguiling talk of "chemical imbalances" that
is pervasive not only in popular culture but also among mental health professionals.
The discussions of the side effects of SSRIs is disconcerting, and Glenmullen
makes a strong case that the drug manufacturers and the psychiatric establishment
have downplayed these serious side effects. He documents all his sources
(there are thirty five pages of notes at the end of the book) and leaves
little room for doubt that there are at least strong reasons to worry about
the effects of Prozac and its relatives. Chapter one is about tics, muscle
spasms, fatigue, and neurological agitation, and it draws parallels to
the effects of the antipsychotic drugs and neurological diseases. Chapter
two is about the effects of going off SSRI medication, which is what he
calls "Prozac backlash." Often people feel bad when they discontinue their
medication, and they conclude that they need to resume taking it. But Glenmullen
argues that in many cases, the proper conclusion is that the medication
should be tapered more carefully and there is often no reason to think
the medication continues to be necessary. The fact that SSRI medication
can have withdrawal effects means that it can be hard to kick the habit
of medication, and is in a sense addictive. This is a conclusion that the
manufacturers of these drugs do not want society to come to.
Chapter three is about the rather well known sexual side effects of
SSRIs and ways to deal with them. More interesting is chapter four, in
the possibility that Prozac and similar medications can make people violent
or suicidal. Glenmullen documents the evidence about the effects of the
Prozac. However, far more alarming are the steps that its manufacturer,
Eli Lilly, has taken to keep this information from the general public and
the psychiatric profession. This story shows the power of corporations
to control information in the United States, and in much of the western
world. Chapter five follows up with similar themes, looking more at how
popular reporting of the causes of depression is so often simplistic and
is biased in favor of pharmacological treatment. There is no serious evidence
that depression is usually caused by depleted levels of the neurotransmitter
serotonin. The evidence that SSRI medication is a better way than placebos
to relieve depression is patchy, and non-existent in the case of children.
Looking at the effects of Prozac, he concludes that "the term 'antidepressant'
is virtually meaningless and seriously misleading" (216). He gives evidence
that the effects of the drugs are very similar to those of stimulants such
as cocaine and amphetamine at prescription doses. He goes on to argue that
HMOs and medical schools are financially implicated with pharmaceutical
companies to such an extent that they have lost their ability to make objective
and unbiassed judgments affecting patients.
The final three chapters deal with alternative treatments from prescription
medication, such as psychotherapy, St. John's Wort, and exercise. They
are effective treatments for depression, anxiety, addiction, and eating
disorders. Often they are more effective and long lasting than using medication
alone.
Glenmullen is not against the use of SSRI medication: he often prescribes
Prozac, Zoloft, Paxil, and the like to his patients. His message is that
those doing the prescribing should be extremely careful when using these
medications, because of all the problems that come with them. These medications
should not be used as a long term solution for mild cases of mental disorder.
They should never be used on their own, but only in combination with other
non-medication approaches. It is alarming that we are so ready to rely
on medication when its benefits are so unclear and there are so many indications
of the problems that come with it.
I have some reservations about the style and length of the book. It
could be shorter than its 338 pages of text, not including the notes. The
final three chapters could be condensed into one, and some of the other
chapters could be shortened. One feature of the book that it shares with
most psychology books aimed at a general readership is its use of case
histories. These are a sine qua non of the publishing industry these
days. The Introduction starts with a student, Ann, who comes in to his
office demanding a prescription for Zoloft because of her depression over
her break up with her boyfriend three years ago. Chapter one starts with
Maura, who is experiencing uncomfortable bodily tics, and soon moves on
to Leslie, who was experiencing extreme apathy. Every section of the book
seems to start with a new patient. It's a formulaic style, and its grows
tiresome. I know that it helps to make rather technical issues more palatable
for a general readership, drawing them into the details, helping relate
the scientific and ethical issues to their own lives. It makes technical
issues less dry to lay readers. Nevertheless, this way of sweetening the
bitter pill of seriousness has its limitations, and I think it could be
used a little more sparingly.
I suspect that part of the problem is that Glenmullen is trying to do
too much in this book. He is giving accounts of the problematic side effects
of SSRI medication, the way that multinational corporations have interfered
with the legal system to protect their reputations, the popular discourse
of medication in modern society, and the multitude of alternatives to medications
as treatments for psychological problems. He is aiming both at general
readers (presumably hoping for a bestseller with a title like Prozac
Backlash) and also more specialized readers. The result is that the
book is sprawling and unwieldy. The solution for readers is to be selective
in which chapters they read. Most health care professionals will have little
to learn from the last three chapters, while lay readers may want to skip
some of the more detailed scientific exposition in the earlier chapters.
Prozac Backlash is an important book. It is not a shrill condemnation
of psychiatric drugs, but rather a powerful reminder that these medications
can have extremely serious side effects. It does not say that most people
should stop taking antidepressants, but instead encourages people to be
conscious of the dangers. Given the way that the medical profession has
been structured, under the influence of the pharmaceutical corporations
and HMOs, patients may have to fight to get the appropriate kind of help
for themselves. Used carefully and in conjunction with other forms of treatment,
SSRI medication can be extremely useful in the treatment of mood disorders,
anxiety, and other psychological disorders. For those readers who are concerned
with not just individual treatment of emotional problems, but with the
wider role of the mental health business in society, Prozac Backlash
provides good reasons to think that the current arrangements are very troubling,
and we need to think hard about how to stop the motive of profit making
playing such a profound and intrusive role in the way that we provide psychiatric
treatment.
© 2001 Christian Perring. First Serial Rights.
|